Last reviewed · How we verify

NCT05103397

High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease

Status unknown Phase 4 Last updated 2 November 2021
What this trial tests

Phase 4 trial testing methyl prednisolone in Anesthesia in 75 participants. Status unknown.

Timeline
16 October 2021
Primary endpoint
15 January 2022
30 January 2022

Quick facts

Lead sponsorAin Shams University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment75
Start date16 October 2021
Primary completion15 January 2022
Estimated completion30 January 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 1 to 16, any sex, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the effect of low dose methylprednisolone versus high dose on inflammatory mediators' level and cardioprotective effect after CPB in correction of congenital acyanotic heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05103397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing